# Exercise and time-restricted and/or dietary feeding jointly improve hepatic lipid homeostasis in diet-induced obese mice

**Authors:** Nicole Power Guerra, Anja U. Bräuer, Markus H. Gräler, Katharina Leyens, Brigitte Vollmar, Angela Kuhla

PMC · DOI: 10.1038/s41598-026-45394-4 · 2026-03-25

## TL;DR

Combining exercise, time-restricted feeding, and diet helps reduce liver fat and improve liver function in obese mice.

## Contribution

The study reveals distinct and additive effects of combined lifestyle interventions on hepatic lipid composition and gene regulation.

## Key findings

- LFD led to the greatest weight loss and normalized liver enzyme levels.
- Combined interventions reduced liver damage markers even under high-fat diet conditions.
- LFD with TRF and/or TM decreased lipogenic gene expression and altered lipid composition.

## Abstract

Obesity and metabolic syndrome are associated with dysregulated hepatic lipid metabolism, contributing to metabolic dysfunction-associated steatotic liver disease (MASLD). Though lifestyle interventions such as a low-fat diet (LFD), treadmill (TM) exercise, and time-restricted feeding (TRF) reduce hepatic lipid accumulation, their combined effects on hepatic lipid composition and lipid metabolism-related gene regulation remain poorly understood. Here, we examined the individual and combined effects of LFD, TM, and/or TRF on liver function, comprehensive hepatic lipidomics, and lipid metabolism-related gene expression in diet-induced obese mice, thereby extending our previous work through detailed lipid class-specific analyses and assessment of interactive intervention effects. Among all interventions, LFD led to the greatest weight loss and normalized plasma aspartate aminotransferase (AST) as well as alanine aminotransferase (ALT) levels. Combined interventions, including TM and TRF, reduced markers of liver damage even under continued HFD conditions compared to HFD alone. LFD with TRF and/or TM decreased the expression of lipogenic genes (Srebf1, Lxrα, Apoe), while expression of genes further involved in lipid synthesis (Fasn and Hmgcr) tended to be increased when TM was combined with either LFD or HFD. β-oxidation-related genes (Ppara, Acox1, Cpt1a) were most downregulated in the LFD groups vs. the HFD + TM group, likely representing a metabolic adaptation to increased lipid mobilization. For the first time, lipidomics analysis demonstrated that in particular LFD alone or in combination with TM most effectively increased sphingomyelin (SM) and dihydrosphingomyelin (DHSM) as well as lysophosphatidylcholine (LPC) and phosphatidylcholine (PC), potentially reflecting compensatory lipid remodeling. Taken together, these findings highlight distinct and additive effects of combined lifestyle interventions on hepatic lipid composition and gene regulation, clearly delineating the novel contributions of the present study and supporting combined dietary and physical strategies as potential approaches to improve hepatic lipid homeostasis and mitigate MASLD development.

The online version contains supplementary material available at 10.1038/s41598-026-45394-4.

## Linked entities

- **Genes:** SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720], NR1H3 (nuclear receptor subfamily 1 group H member 3) [NCBI Gene 10062], APOE (apolipoprotein E) [NCBI Gene 348], FASN (fatty acid synthase) [NCBI Gene 2194], HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156], PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465], ACOX1 (acyl-CoA oxidase 1) [NCBI Gene 51], CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374]
- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), obesity (MONDO:0011122), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Genes:** Srebf2 (sterol regulatory element binding factor 2) [NCBI Gene 20788] {aka SREBP-2, SREBP2, SREBP2gc, bHLHd2, lop13, nuc}, Acox1 (acyl-Coenzyme A oxidase 1, palmitoyl) [NCBI Gene 11430] {aka AOX, Acox, D130055E20Rik, Paox}, Rps18 (ribosomal protein S18) [NCBI Gene 20084] {aka H-2Ke3, H2-Ke3, Ke-3, ke3}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 20787] {aka ADD1, SREBP1, bHLHd1}, Alb (albumin) [NCBI Gene 11657] {aka Alb-1, Alb1, BCL001, BCL002, BPL001}, Lep (leptin) [NCBI Gene 16846] {aka ob, obese}, Hmgcr (3-hydroxy-3-methylglutaryl-Coenzyme A reductase) [NCBI Gene 15357] {aka HMG-CoAR, Red}, Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Cpt1a (carnitine palmitoyltransferase 1a, liver) [NCBI Gene 12894] {aka C730027G07, CPTI, Cpt1}, Nr1h3 (nuclear receptor subfamily 1, group H, member 3) [NCBI Gene 22259] {aka LXR, RLD1, Unr1}, Cpt2 (carnitine palmitoyltransferase 2) [NCBI Gene 12896] {aka CPTII}, Pcx (pyruvate carboxylase) [NCBI Gene 18563] {aka Pc, Pcb}, Fasn (fatty acid synthase) [NCBI Gene 14104] {aka A630082H08Rik, FAS}, Apoe (apolipoprotein E) [NCBI Gene 11816] {aka Apo-E}
- **Diseases:** insulin resistance (MESH:D007333), Liver damage (MESH:D056486), metabolic disease (MESH:D008659), cervical dislocation (MESH:D002575), weight gain (MESH:D015430), vascular dysfunction (MESH:D002561), hyperlipidemia (MESH:D006949), PC (MESH:C535298), HFD (MESH:D004620), hypertriglyceridemia (MESH:D015228), Obesity (MESH:D009765), weight loss (MESH:D015431), LFD (MESH:D009800), reduction in body weight (MESH:D001835), overweight (MESH:D050177), liver dysfunction (MESH:D017093), Metabolic syndrome (MESH:D024821), abdominal obesity (MESH:D056128), hypertension (MESH:D006973), metabolic and cardiovascular diseases (MESH:D002318), hyperglycemia (MESH:D006943), MASLD (MESH:D008107), hepatic steatosis (MESH:D005234), liver cirrhosis (MESH:D008103)
- **Chemicals:** beta-hydroxybutyrate (MESH:D020155), N2O (MESH:D009609), PC (MESH:D010713), unsaturated fatty acids (MESH:D005231), LPA (MESH:D010649), isoflurane (MESH:D007530), phosphocholines (MESH:D010767), DHSM (-), glycosphingolipids (MESH:D006028), Cholesterol (MESH:D002784), CoA (MESH:D003065), Cer (MESH:D002518), BMP (MESH:C012786), chloroform (MESH:D002725), phospholipid (MESH:D010743), MonHex (MESH:C013870), SYBR  Green (MESH:C098022), LPC (MESH:D008244), lactate (MESH:D019344), fatty acid (MESH:D005227), sphingolipids (MESH:D013107), methanol (MESH:D000432), LPE (MESH:C008301), lysophosphatidic acid (MESH:C032881), acylcarnitines (MESH:C116917), carbohydrates (MESH:D002241), SM (MESH:D013109), acetyl-CoA (MESH:D000105), BHT (MESH:D002084), hydrochloric acid (MESH:D006851), sphingosine (MESH:D013110), malonyl-CoA (MESH:D008316), lysophospholipids (MESH:D008246), formic acid (MESH:C030544), fat (MESH:D005223), nitrogen (MESH:D009584), Lipid (MESH:D008055), TG (MESH:D014280), ketone (MESH:D007659), water (MESH:D014867)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13031764/full.md

---
Source: https://tomesphere.com/paper/PMC13031764